Market Overview

Benzinga's Top Pre-Market Losers

Share:
Related FOLD
US Stock Futures Jump Ahead Of Wholesale Inventories Data
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report (Seeking Alpha)
Related GSK
Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices
New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In Monkeys
WHO decision on Ebola mass vaccination not until August or later (Seeking Alpha)

Amicus Therapeutics (NASDAQ: FOLD) shares dropped 46.97% to $3.06 in pre-market trading. Amicus Therapeutics and GlaxoSmithKline plc (NYSE: GSK) today announced the 6-month primary treatment period results from the first Phase 3 global registration study.

Allscripts Healthcare Solutions (NASDAQ: MDRX) shares fell 16.48% to $8.92 in the pre-market trading. Allscripts appointed Paul Black as its CEO.

Accenture plc (NYSE: ACN) dipped 5.21% to $66.73 in the pre-market session. Accenture projects Q2 revenue of $6.9 billion of $7.15 billion, versus analysts' estimates of $7.14 billion.

Bed Bath & Beyond (NASDAQ: BBBY) dipped 4.86% to $57.35 in the pre-market session. Bed Bath & Beyond issued downbeat fourth-quarter earnings forecast. The company's board also authorized a new $2.5 billion share repurchase program.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets

 

Related Articles (BBBY + ACN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content